Therefore, the findings suggest that METTL3 is a novel oncogene in the pathogenesis of CML and a potential therapeutic target for TKIs-resistant CML. The gene discussed is METTL3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.